PND3 ANTI-EPILEPTIC MEDICATION DRUG FORMULATION CHANGES AND THEIR RELATIONSHIP TO OUTCOMES (AMBULANCE, EMERGENCY DEPARTMENT AND INPATIENT EVENTS)  by Mann, TA et al.
(p < 0.001 for both) from post-index (mean = US$4288.80, and
US$2581.77 respectively). CONCLUSIONS: Approximately one
in ten patients receiving care for epilepsy in an emergent setting
presents with co-occurring injuries according medical claims.
The cost of care for possible re-establishment of epilepsy control
and treating co-occurring injuries is signiﬁcant when compared
to the time period prior to seizure.
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HUNTINGTON’S DISEASE:WHERE HAVE WE BEEN?
Samuels E, Stoddart SD, Lock K, Karia R
Heron Evidence Development Ltd, Letchworth Garden City, UK
OBJECTIVES: The completion of the genome project was
expected to lead to treatments for genetically-linked disorders.
In many cases this has not occurred. Our aim was to investigate
the published research in one such disorder, Huntington’s
disease (HD), in order to assess the current knowledge in this
area. METHODS: A systematic search of Medline was con-
ducted using a search ﬁlter for RCTs alongside keyword search
strings for HD. Identiﬁed citations were ﬁrst- and second-
passed by two reviewers to determine inclusion/exclusion and
reconciled by a third where decisions disagreed. Top-line data
relating to treatment, included patients, and outcome was then
extracted by two reviewers based on the abstract only. Differ-
ences were reconciled by a third reviewer. keyword search
strings for HD. Identiﬁed citations were ﬁrst- and second-
passed by two reviewers to determine inclusion/exclusion and
reconciled by a third where decisions disagreed. Top-line data
relating to treatment, included patients, and outcome was then
extracted by two reviewers based on the abstract only. Differ-
ences were reconciled by a third reviewer. RESULTS: A total of
397 probable RCTs were identiﬁed: 262 were excluded as non-
RCTs and 135 included for extraction. Twenty-seven abstracts
were unavailable, thus the ﬁnal analysis is based on 108
studies. Of these studies, 29 were conducted in Europe, 29 in
USA, 2 in Mexico, 2 in Israel, and one in Australia and
Canada. The remaining studies did not state country of origin.
Across all included studies 67 treatments were investigated,
with between 3 and 537 patients enrolled. Almost all studies
enrolled 30 individuals or less. Fifty-ﬁve studies reported that
the intervention(s) was effective; 41 reported no efﬁcacy (12 did
not report the results). CONCLUSIONS: The majority of
research in HD has been conducted in Western Europe and the
United States. A wide variety of potential treatments have been
investigated, many of which were ineffective for the treatment
of HD. However, most research enrolled few patients and may
thus lack power to detect any treatment effects. To date no
genetically-related treatments have been developed, which is
surprising given the identiﬁcation of the HD gene in 1993.
Further research into a cure for HD is warranted.
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OBJECTIVES: To determine whether epileptic patients with evi-
dence of an epilepsy-related inpatient, emergency department, or
ambulance treatment claim (deﬁned as an event) and matching
epileptic patients with no evidence of an event differ with respect
to anti-epileptic medication drug formulation changes (either
brand to generic switching or switching between “A-rated” for-
mulations). METHODS: A retrospective case control design
analysis was conducted utilizing PharMetrics® claims between
January 2005 and June 2007. Cases were identiﬁed using an
ICD-9 code of 345.xx and had an epileptic event requiring a
subsequent service code for any of the three care settings of
interest. All patients (cases and controls) were between 12 and 64
years of age, had continuous coverage for at least 6 months and
145 days’ supply of medication prior to their index date. Sta-
tistical analyses were conducted using SAS®. RESULTS: There
were 11,360 patients that met inclusion criteria for analysis (991
cases and 10,369 controls). When controlling for age, sex, region
of the country, and type of seizure diagnosis, the odds ratio of the
occurrence of an event between those who switched medication
and those who did not was 1.91 (CI = 1.53 to 2.39). In addition,
a propensity score calculation was conducted to select 991
matched controls for the case group. When performing a logistic
regression using the same variables as above, only switching was
still a signiﬁcant predictor of an event (odds ratio = 1.45;
CI = 1.04 to 1.93) CONCLUSIONS: This analysis found an
association between patients receiving epilepsy care in an emer-
gency department, ambulance, or inpatient setting and the prior
occurrence of formulation switching involving A-rated anti-
epileptic generic medications.
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OBJECTIVES: To compare outcomes of multiple sclerosis (MS)
patients treated with either glatiramer acetate (GA) or inter-
feron beta 1-b (IFN-b-1b) for subcutaneous administration.
METHODS: Data were obtained from i3’s Lab Rx Database
from July 2001 to June 2006. We established an “intent-to-
treat” (ITT) cohort (N = 842) of patients diagnosed with MS
who began therapy on either GA or IFN-b-1b and had con-
tinuous insurance coverage from 6 months before to 24 months
after the date when they began taking the medication. We also
created a “continuous use” (CU) cohort (n = 418) of individu-
als who, in addition to the criteria above, used either GA or
IFN-b-1b within 28 days of the end of the two year post-
period. Using multivariate regressions, we examined both the
two-year total direct medical costs and the likelihood of relapse
associated with the use of each of these MS medications. We
deﬁned relapse as either being hospitalized with a diagnosis of
MS or being diagnosed with MS during an outpatient visit and
then prescribed steroids within a 7-day period. All regression
analyses evaluated a wide range of factors that may affect out-
comes. RESULTS: In the ITT cohort, compared to those who
started therapy with IFN-b-1b, patients who started therapy on
GA had a signiﬁcantly lower two-year risk of relapse (13.54%
v 5.31%; P = 0.0006). In the CU cohort, compared to those
who used IFN-b-1b, patients who used GA also had a signiﬁ-
cantly lower two-year risk of relapse (10.919% v 2.09%;
P = 0.0018) and signiﬁcantly lower total medical costs ($53,185
v $48,130; P = 0.0345). CONCLUSIONS: Results from this
study indicate that, compared to the use of IFN-b-1b, GA use
is associated with signiﬁcantly lower probability of relapse.
Additionally, when comparing continuous users of GA or IFN
beta-1b, there were signiﬁcantly lower two-year total direct
medical costs associated with GA use.
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